Fusidic Acid Analogues with Cyclic Side Chains for Resistance Management
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Fusidic acid, a potent antibiotic, faces challenges due to high resistance frequency and drastic shifts in minimum inhibitory concentration (MIC) in bacterial strains, limiting its wider usage and necessitating elevated dosing, while existing derivatives fail to improve antibacterial activity against Gram-positive pathogens.
Innovation Solution
Development of novel fusidic acid analogues with modified side chains, such as FA-CP, which exhibit improved resistance profiles and retain potent antibacterial activity, including against resistant strains, through systematic synthesis and evaluation of structural modifications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If fusidic acid is used to treat Gram-positive infections, then potent antibacterial activity is achieved, but high resistance frequency and drastic MIC shifts occur
Solution Approach 1:
The patent modifies the chemical structure of fusidic acid by changing parameters such as the side chain configuration (introducing cyclic groups at positions 26 and 27), oxidation state of the hydroxyl group, and substituent patterns. These parameter changes create analogues like FA-CP that maintain binding affinity to EF-G while reducing the frequency of resistance mutations and minimizing MIC shifts when resistance occurs.
Solution Approach 2:
The invention creates composite molecular structures by combining the core fusidane ring system with modified side chains containing cyclic groups (cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl rings). This composite approach integrates the proven antibacterial scaffold with novel structural elements that improve the resistance profile while retaining Gram-positive specificity.
2Reliability
If elevated dosing is administered to overcome resistance, then antibacterial efficacy is maintained, but drug exposure and potential toxicity increase
Solution Approach 1:
By modifying molecular parameters to create fusidic acid analogues with improved resistance profiles, the patent enables maintenance of therapeutic efficacy at lower doses. The structural modifications enhance the drug's ability to overcome resistance mechanisms, allowing effective treatment without the need for elevated dosing regimens that increase drug exposure and potential adverse effects.
3Ease of manufacture
If single enzyme inhibitors are used, then targeted mechanism of action is achieved, but elevated MIC shifts upon resistance occur
Solution Approach 1:
The patent applies parameter changes to the inhibitor structure by introducing cyclic groups and modifying substituents on the fusidane core. These modifications alter the interaction profile with the EF-G enzyme, creating a more robust binding mode that tolerates fewer resistance mutations and minimizes MIC shifts while preserving the targeted mechanism of action at the ribosomal E-site.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
FA-CP demonstrates reduced shifts in MIC upon resistance, improved resistance frequency, and retains efficacy against Fusidic acid-resistant strains, offering a potential solution for treating bacterial infections with a favorable resistance profile.
Implementation Method 1
Its mechanism of action involves inhibition of protein synthesis by stabilizing the elongation factor G (EF-G) complex, resulting in the truncation of peptide elongation
Data Source
AI summary
Novel Fusidic Acid (FA) based compounds that have equivalent potency against clinical isolates of Staphylococcus aureus (S. aureus) and Enterococcus faecium (E. faecium) as well as an improved resistance profile in vitro when compared to FA. Importantly, the new compounds display efficacy against a FA-resistant strain of Staphylococcus aureus in a soft-tissue murine infection model. This disclosure delineates the structural features of FA necessary for potent antibiotic activity and demonstrates that the resistance profile can be improved for this scaffold and target.